Compare Sanofi SA (SNY) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TeraWulf Inc — how do they compare? Sanofi SA trades at $40.14 (market cap $95.18B), while TeraWulf Inc trades at $13.69 (market cap $6.81B). The key difference: Sanofi SA is far larger — about 14× TeraWulf Inc's market cap, and Sanofi SA pays a 6.01% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and TeraWulf Inc for 17 Days on average.
| SNY | WULF | |
|---|---|---|
Market Cap | $95.18B | $6.81B |
Volume | 2,995,646 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $52.34 | $28.98 |
52-Week Low | $39.51 | $10.99 |
Typical Hold Time | 94 Days | 17 Days |
Enterprise Value | $114.48B | $9.43B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid a challenging fundamental backdrop with significant losses and negative margins. The stock shows technical bearish signals with moving averages indicating selling pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights the company's pivot to AI data center operations, with positive analyst coverage despite poor financial performance.
While analyst consensus remains strongly bullish with a $34.92 price target, fundamental weaknesses including negative net income margin of -1,179.94% and high valuation ratios present substantial risks. The company's transition to AI hosting offers growth potential but requires careful monitoring of cash flow sustainability and competitive positioning in the evolving data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
